Analyst Price Targets — PHVS
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| July 15, 2026 9:32 am | Yanan Zhu | Wells Fargo | $55.00 | $34.42 | TheFly | Pharvaris initiated with an Overweight at Wells Fargo |
| June 25, 2026 10:48 am | Maxwell Skor | Morgan Stanley | $46.00 | $33.29 | TheFly | Pharvaris price target raised to $46 from $41 at Morgan Stanley |
| May 13, 2026 9:53 am | — | UBS | $74.00 | $31.25 | TheFly | Pharvaris price target lowered to $74 from $75 at Citizens |
| April 8, 2026 8:39 pm | — | Wolfe Research | $42.00 | $27.56 | TheFly | Pharvaris initiated with an Outperform at Wolfe Research |
| March 9, 2026 9:20 am | — | RBC Capital | $52.00 | $26.51 | TheFly | Pharvaris initiated with an Outperform at RBC Capital |
| December 4, 2025 12:35 pm | — | Oppenheimer | $50.00 | $29.37 | TheFly | Pharvaris price target raised to $50 from $44 at Oppenheimer |
| December 4, 2025 12:23 pm | Debjit Chattopadhyay | Guggenheim | $39.00 | $29.37 | TheFly | Pharvaris price target raised to $39 from $32 at Guggenheim |
| December 4, 2025 12:12 am | Maxwell Skor | Morgan Stanley | $41.00 | $29.37 | TheFly | Pharvaris price target raised to $41 from $37 at Morgan Stanley |
| December 3, 2025 7:56 pm | — | Leerink Partners | $38.00 | $29.37 | TheFly | Pharvaris price target raised to $38 from $28 at Leerink |
| October 15, 2025 10:09 am | — | H.C. Wainwright | $60.00 | $20.96 | TheFly | Pharvaris initiated with a Buy at H.C. Wainwright |
Latest News for PHVS
Does Pharvaris N.V. (PHVS) have what it takes to be a top stock pick for momentum investors?
The mean of analysts' price targets for Pharvaris (PHVS) points to a 36.2% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
ZUG, Switzerland, July 06, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced that the U.S. Food and Drug Administration…
ZUG, Switzerland, June 15, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated angioedema, such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), summarized the presentations from the European Academy of Allergy…
ZUG, Switzerland, June 11, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), today announced the annual general meeting of shareholders…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for PHVS.
U.S. House Trading
No House trades found for PHVS.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.